

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) Dirk ESSER et al.

Appl. No.: 10/526,808

Filing Date: March 4, 2005

Title: MODIFIED THERAPEUTIC AGENTS



Attorney Docket No.: 37945-0068

Confirmation No.: 5544

Group Art Unit: 1645

Examiner: Unassigned

RESPONSE TO NOTIFICATION TO COMPLY

United States Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:


Applicants respond herewith to the Notification to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed July 8, 2005, in the above-referenced application. Applicants believe no fees are due at this time, however, the Commissioner is hereby authorized to charge any fees which may be required to Deposit Account No. 08-1641.

Respectfully submitted,

September 6, 2005

Date

Heller Ehrman LLP
1717 Rhode Island Avenue, N.W.
Washington, D.C. 20036
Telephone: (202) 912-2000
Facsimile: (202) 912-2020
Customer No. 26633



John P. Isacson
Reg. No. 33,715
Attorney for Applicant



Page 1 of 2
Rec'd PCT/PTO 06 SEP 2005


UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/526,808	Dirk Esser	37945-0068

26633
HELLER EHRMAN WHITE & MCAULIFFE LLP
1717 RHODE ISLAND AVE, NW
WASHINGTON, DC 20036-3001

INTERNATIONAL APPLICATION NO.	
PCT/GB03/03867	
LA. FILING DATE	PRIORITY DATE
09/05/2003	09/05/2002



CONFIRMATION NO. 5544

371 FORMALITIES LETTER



OC00000016476423

Date Mailed: 07/08/2005

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/526,808	PCT/GB03/03867	37945-0068

Rec'd PCT/PTO 06 SEP 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#9

Applicant(s) Dirk ESSER et al.

Appl. No.: 10/526,808

Filing Date: March 4, 2005

Title: MODIFIED THERAPEUTIC AGENTS



Attorney Docket No.: 37945-0068

Confirmation No.: 5544

Group Art Unit: 1645

Examiner: Unassigned

**STATEMENT TO SUPPORT FILING AND
SUBMISSION OF SEQUENCE LISTING**

United States Patent and Trademark Office
Customer Service Window, Mail Stop Sequence
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states upon information and belief that:

1. the submission, filed herewith in accordance with Section 801(a), does not include new matter; and

2. the content of the included paper copy and the included computer readable copy of the Sequence Listing, submitted in accordance with Section 801(a), respectively, are the same.

Respectfully submitted,

John P. Isacson
Reg. No. 33,715
Attorney for Applicant

September 6, 2005
Date

Heller Ehrman LLP
1717 Rhode Island Avenue, N.W.
Washington, D.C. 20036
Telephone: (202) 912-2000
Facsimile: (202) 912-2020
Customer No. 26633